References

1 Comess KM, Schurdak ME: Affinity-based screening techniques to enhance lead discovery. Curr Opin Drug Discov Devel 2004, 7, 411-416.

2 Bleicher KH, Bohm H-J, Müller K, Alanine AI: Hit and lead generation: beyond high-throughput screening. Nat Rev Drug Discov 2003, 2, 369378.

3 Walters WP, Namchuk M: Designing screens: how to make your hits a hit. Nat Rev Drug Discov 2003, 2, 259266.

4 Geoghegan KF, Kelly MA: Biochemical applications of mass spectrometry in pharmaceutical drug discovery. Mass Spectrom Rev 2005, 24, 347-366.

5 Freundlieb S, Garner J: New Drugs 2002, 3, 54-60.

6 Pantoliano MW, Petrella EC, Kwasnoski JD, Lobanov VS, Myslik J, GrafE, Carver T, Asel E, Springer BA, Lane P, Salemme FR: High-Density miniaturized thermal shift assays as a general strategy for drug discovery. J Biomol Screen 2001, 6, 429-440.

7 Powell KD, Fitzgerald MC: High-throughput screening assay for the tunable selection of protein ligands. J Comb Chem 2004, 6, 262-269.

8 Zhu MM, Rempel DL, Du Z, Gross ML: Quantification of protein-ligand interactions by mass spectrometry, titration, and H/D exchange: PLIMSTEX. J Am Chem Soc 2003, 125, 5252-5253.

9 Zhu MM, Hambley D, Gross ML: Quantitation of protein-ligand interactions in solution by H/D exchange (PLIMSTEX), chapter 11.

10 Comess KM, Schurdak ME, Voorbach MJ, Coen M, Trumbull JD, Yang H, Gao L, Tang H, Cheng X, Lerner CG, McCall JO, Burns DJ, Beutel BA: An ultra-efficient affinity-based high throughput screening process: application to bacterial cell wall biosynthesis enzyme MurF. J Biomol Screen 2006, 11, 736-742.

11 Siegel MM, Tabei K, Bebernitz GA, Baum EZ: Rapid methods for screening low molecular mass compounds non-covalently bound to proteins using size exclusion and mass spectrometry applied to inhibitors of human cytomegalovirus protease. J Mass Spectrom 1998, 33, 264-273.

12 Lenz GR, Nash HM, Jindal S: Chemical ligands, genomics, and drug discovery. Drug Discov Today 2000, 5, 145-156.

13 Muckenschnabel I, Falchetto R, Mayr LM, Filipuzzi I: SpeedScreen: labelfree liquid chromatography-mass spectrometry-based high-throughput screening for the discovery of orphan protein ligands. Anal Biochem 2004, 324, 241-249.

14 Zehender H, Le Goff F, Lehmann N, Filipuzzi I, Mayr LM: SpeedScreen: The ''missing link'' between genomics and lead discovery. J Biomol Screen 2004, 9, 498-505.

15 Siegel MM: Drug screening using gel permeation chromatography spin columns coupled with ESI-MS, chapter 2.

16 Annis DA, Nazef N, Chuang CC, Scott MP, Nash HM: A general technique to rank protein-ligand binding affinities and determine allosteric versus direct binding site competition in compound mixtures. J Am Chem Soc 2004, 126, 1549515503.

17 Coburn CA, Stachel SJ, Li YM, Rush DM, Steele TG, Chen-Dodson E, Holloway MK, Xu M, Huang Q, Lai MT, DiMuzio J, Crouthamel MC, Shi XP, Sardana V, Chen Z, Munshi S, Kuo L, Makara GM, Annis DA, Tadikonda PK, Nash HM, Vacca JP, Wang T: Identification of a small molecule nonpeptide active site beta-secretase inhibitor that displays a nontraditional binding mode for aspartyl proteases. J Med Chem 2004, 47, 6117-6119.

19 Annis A, Chuang C-C, Nazef N: An affinity selection-mass spectrometry system for the discovery and characterization of protein-ligand interactions, chapter 3.

20 Shin YG, van Breemen RB: Analysis and screening of combinatorial libraries using mass spectrometry. Biopharm Drug Dispos 2001, 22, 353-372.

21 van Breemen RB, Huang CR, Nikolic D, Woodbury CP, Zhao YZ, Venton DL: Pulsed ultrafiltration mass spectrometry: a new method for screening combinatorial libraries. Anal Chem 1997, 69, 2159-2164.

22 Johnson BM, Nikolic D, van Breemen RB: Applications of pulsed ultrafiltration-mass spectrometry. Mass Spectrom Rev 2002, 21, 76-86.

23 Wieboldt R, Zweigenbaum J, Henion J: immunoaffinity ultrafiltration with ion spray HPLC/MS for screening small-molecule libraries. Anal Chem 1997, 69, 1683-1691.

24 van Elswijk DA, Tjaden UR, van der Greef J, Irth H: Mass spectrometry-based bioassay for the screening of soluble orphan receptors. Int J Mass Spectrom 2001, 210/211, 625-636.

25 Irth H: Continuous-flow systems for ligand binding and enzyme inhibition assays based on mass spectrometry, chapter 5.

26 Hughes DE, Waters JL, Dunayevskiy YM: Capillary electrophoretic method to detect target-binding ligands and to determine their relative affinities. US Patent 6 524 866, 2003.

27 Hughes DE, Karger BL, Waters JL, Dunayevshiy YM: Method to detect and analyze tight-binding ligands in complex biological samples using capillary electrophoresis and mass spectrometry. US Patent 6 432 651, 2002.

28 Griffey RH, Hofstadler SA, Sannes-Lowery KA, Ecker DJ, Crooke ST: Determinants of aminoglycoside-binding specificity for rRNA by using mass spectrometry. Proc Natl Acad Sci USA 1999, 96, 10129-101233.

29 Cummins LL, Chen S, Blyn LB, Sannes-Lowery KA, Drader JJ, Griffey RH, Hofstadler SA: Multitarget affinity/specificity screening of natural products: finding and characterizing high-affinity ligands from complex mixtures by using high-performance mass spectrometry. J Nat Prod 2003, 66, 1186-1190.

30 Hofstadler SA, Sannes-Lowery KA: Interrogation of concovalent complexes by ESI-MS: A powerful platform for high throughput drug discovery, chapter 10.

31 Siegel MM: Early discovery drug screening using mass spectrometry. Curr Top Med Chem 2002, 2, 13-33.

32 Goodnow RA Jr.: Current practices in generation of small molecule new leads. J Cell Biochem 2001, 37, 13-21.

33 Goodnow R Jr: Small molecule lead generation processes for drug discovery. Drugs Future 2002, 27, 1165-1180.

34 Martin YC, Kofron JL, Traphagen LM: Do structurally similar molecules have similar biological activity? J Med Chem 2002, 45, 4350-4358.

35 El Zoeiby A, Sanschagrin F, Levesque RC: Structure and function of the Mur enzymes: development of novel inhibitors. Mol Microbiol 2003, 47, 1-12.

36 Gu YG, Florjancic AS, Clark RF, Zhang T, Cooper CS, Anderson DD, Lerner CG, McCall JO, Cai Y, Black-Schaefer CL, Stamper GF, Hajduk PJ,

Beutel BA: Structure-activity relationships of novel potent MurF inhibitors. Bioorg Med Chem Lett 2004, 14, 267-270.

37 Qian J, Voorbach MJ, Huth JR, Coen ML, Zhang H, Ng S-C, Comess KM, Petros AM, Rosenberg SH, Warrior U, Burns DJ: Discovery of novel inhibitors of Bcl-xL using multiple high-throughput screening platforms. Anal Biochem 2004, 328, 131-138.

38 Hajduk PJ, Meadows RP, Fesik SW: NMR-based screening in drug discovery. Q Rev Biophys 1999, 32, 211-240.

39 Comess KM, Trumbull JD, Park C, Chen Z, Judge RA, Voorbach MJ, Coen M, Gao L, Tang H, Kovar P, Cheng X, Schurdak ME, Zhang H, Sowin T, Burns DJ: Kinase drug discovery by affinity selection/mass spectrometry (ASMS): application to DNA damage checkpoint kinase Chk1. J Biomol Screen 2006, 11, 743754.

40 Lipinski CA, Lombardo F, Dominy BW, Feeney PJ: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997, 23, 3-25.

41 Oprea TI, Davis AM, Teague SJ, Leeson PD: Is there a difference between leads and drugs? A historical perspective. J Chem Inf Comput Sci 2001, 41, 1308-1315.

42 Teague SJ, Davis AM, Leeson PD, Oprea T: The design of leadlike combinatorial libraries. Angew Chem Int Ed Engl 1999, 38, 37433748.

43 Rishton GM: Nonleadlikeness and leadlikeness in biochemical screening. Drug Discov Today 2003, 8, 86-96.

44 McGovern SL, Caselli E, Grigorieff N, Shoichet BK: A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J Med Chem 2002, 45, 1712-17122.

45 McGovern SL, Shoichet BK: Kinase inhibitors: not just for kinases anymore. J Med Chem 2003, 46, 1478-1483.

46 Golebiowski A, Klopfenstein SR, Portlock DE: Lead compounds discovered from libraries: part 2. Curr Opin Chem Biol 2003, 7, 1-18.

47 van Breemen RB, Nikolic D, Xu X, Xiong Y, van Lieshout M, West CE, Schilling AB: Development of a method for quantitation of retinol and retinyl palmitate in human serum using high-performance liquid chromatography-atmospheric pressure chemical ionization-mass spectrometry. J Chromatogr A 1998, 794, 245-251.

48 Zhao YZ, van Breemen RB, Nikolic D, Huang CR, Woodbury CP, Schilling A, Venton DL: Screening solution-phase combinatorial libraries using pulsed ultrafiltration/ electrospray mass spectrometry. J Med Chem 1997, 40, 4006-4012.

49 Nikolic D, van Breemen RB: Screening for inhibitors of dihydrofolate reductase using pulsed ultrafiltration mass spectrometry. Comb Chem High Throughput Screen 1998, 1, 47-55.

Was this article helpful?

0 0

Post a comment